Ra pharmaceuticals, inc. (RARX)
CashFlow / Quarterly
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Cash flows from operating activities
Net loss

-36,777

-24,975

-21,897

-19,039

-16,195

-16,504

-15,746

-16,498

-15,141

-15,275

-12,663

-11,360

-10,888

-8,114

-4,806

-5,056

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

13

543

533

530

411

414

386

386

403

391

384

346

273

332

398

271

Stock-based compensation

3,897

3,813

3,445

2,890

2,142

1,795

1,812

1,946

1,726

1,597

1,232

1,018

505

250

146

125

Other, net

0

-25

0

-49

-

-

-

-

-

-

-

-

-69

4

705

-724

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

2,026

1,493

2,140

1,326

159

-644

1,226

-692

1,453

-117

-299

-14

1,021

-550

-1,710

2,129

Accounts payable and accrued expenses

5,862

102

1,943

-887

1,883

-64

1,358

-2,051

1,049

1,059

1,904

-2,000

1,111

408

2,360

139

Operating lease liabilities

-141

-376

-251

-239

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

-

-

-

-

-

-

20

19

-326

-2,102

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-37

-1,825

Other, net

-

-

-

-

-197

114

110

-8

-180

104

76

19

-

-

-

-

Net cash used in operating activities

-28,611

-22,361

-18,367

-18,022

-12,074

-13,829

-13,526

-15,517

-13,651

-12,214

-8,913

-12,001

-9,024

-7,495

325

-5,649

Purchase of property and equipment

236

213

221

195

119

357

529

29

22

262

649

479

611

1,273

3,164

57

Net cash used in investing activities

-236

-213

-221

-195

-119

-357

-529

-29

-22

-262

-649

-479

-738

-1,270

-3,034

-54

Cash flows from financing activities
Proceeds from common stock offering, net of underwriter discounts

-

-

-

-

140,532

0

0

54,482

-

-

-

-

-

-

-

-

Proceeds from sale of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

Payment of common stock offering costs

0

-46

343

243

32

0

176

195

-

-

-

-

-

-

-

-

Payments related to restricted stock units vesting

0

0

99

484

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of stock options and ESPP shares

1,237

997

986

769

-

-

-

-

22

79

124

41

-

-

-

-

Net cash provided by financing activities

1,237

141,573

544

42

140,956

188

-10

54,287

-37

-38

794

41

-

-

-

-

Net change in cash, cash equivalents and restricted cash

-27,610

118,999

-18,044

-18,175

128,763

-13,998

-14,065

38,741

-13,710

-12,514

-8,768

-12,439

-

-

-

-5,703

Noncash investing and financing activity:
Common stock offering costs incurred but unpaid at period end

-

-

-

-

-

-

-

176

-

-

-

-

-

-

-

-

Changes in liabilities and prepaid expenses related to fixed asset additions

-

-

-

93

-

-

-

355

-

-

-

-

-

-

-

-